| Bio-CAR-T BS Study (NCT05366569) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2022-04-26 |
| Bright Ideas - CIN Feasibility Study (NCT04929899) | The Hospital for Sick Children | 2022-03-01 |
| Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data (NCT06392763) | Novartis Pharmaceuticals | 2021-08-03 |
| Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation (NCT06865352) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2021-02-13 |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) (NCT05349201) | Novartis Pharmaceuticals | 2020-12-09 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (NCT04029688) | Hoffmann-La Roche | 2020-01-27 |
| Animal Assisted Interactions With Animal Robot in the Intensive Care Unit (ICU) (NCT05075395) | University of Nebraska | 2019-07-01 |
| Safety and Efficacy Evaluation of CD19-UCART (NCT03229876) | Bioray Laboratories | 2019-06-01 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (NCT03849651) | St. Jude Children's Research Hospital | 2019-01-31 |
| Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL (NCT03740334) | Dana-Farber Cancer Institute | 2019-01-30 |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study (NCT03260101) | Cellect Biotechnology | 2018-06-10 |
| C-CAR011 Treatment in Subjects With ALL After HSCT (NCT03327285) | Peking University People's Hospital | 2018-03-01 |
| A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma (NCT03181126) | AbbVie | 2017-11-27 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (NCT03236857) | AbbVie | 2017-11-08 |
| International Study for Treatment of High Risk Childhood Relapsed ALL 2010 (NCT03590171) | Charite University, Berlin, Germany | 2017-09-01 |
| Genetic Study of Familial Acute Lymphoblastic Leukemia (NCT03067584) | St. Jude Children's Research Hospital | 2017-05-09 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS (NCT02730299) | Gamida Cell ltd | 2016-12-16 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (NCT02790515) | St. Jude Children's Research Hospital | 2016-07-14 |
| Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older (NCT02647190) | Memorial Sloan Kettering Cancer Center | 2016-01-01 |
| Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment (NCT02269579) | Jazz Pharmaceuticals | 2015-04-01 |
| Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT02303821) | Amgen | 2015-02-16 |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation (NCT02259348) | St. Jude Children's Research Hospital | 2014-10-01 |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (NCT02226861) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-26 |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome (NCT02212561) | St. Jude Children's Research Hospital | 2014-08-01 |
| An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients (NCT02238925) | Jazz Pharmaceuticals | 2014-07-01 |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs (NCT02200380) | Celldex Therapeutics | 2014-07-01 |
| International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 (NCT01802814) | Charite University, Berlin, Germany | 2014-05-01 |
| A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL (NCT02046694) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-01-06 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (NCT01885897) | Masonic Cancer Center, University of Minnesota | 2013-11-11 |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM (NCT01816230) | Gamida Cell ltd | 2013-04-01 |
| Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (NCT01735955) | Novartis Pharmaceuticals | 2013-03-29 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL (NCT01439347) | Spectrum Pharmaceuticals, Inc | 2012-03-01 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell (NCT01660607) | Stanford University | 2012-02-09 |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) (NCT01351545) | Center for International Blood and Marrow Transplant Research | 2011-10-01 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies (NCT01221857) | Gamida Cell ltd | 2010-11-01 |
| Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9). (NCT01282593) | Rennes University Hospital | 2010-11-01 |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells (NCT01050764) | Everett Meyer | 2009-06-01 |
| Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (NCT00840853) | Baylor College of Medicine | 2009-04-01 |
| Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study (NCT02894645) | National University Hospital, Singapore | 2008-10-01 |
| Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL (NCT01305655) | Nordic Society for Pediatric Hematology and Oncology | 2008-07-01 |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation (NCT00672152) | Michael Morse, MD | 2007-06-01 |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia (NCT00495079) | Spectrum Pharmaceuticals, Inc | 2007-05-01 |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies (NCT00145613) | St. Jude Children's Research Hospital | 2003-06-01 |
| MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT04559555) | Novartis Pharmaceuticals | |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |